Alemtuzumab

References

• Winter G, Milstein C. Man-made antibodies. Nature349, 293–299 (1991).
   PubMed Web of Science ®Google Scholar
• Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc.)39(Suppl. C), 1–16 (2003).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results. Clin. Cancer Res.10, 5327–5334 (2004).
   PubMed Web of Science ®Google Scholar
• Pathan N, Hariharan K, Hopkins M et al. Induction of apoptosis by IDEC-152 in lymphoma cells. Blood98 (2001) (Abstract 367).
   Google Scholar
• Mone AP, Huang P, Pelicano H et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood103, 1846–1854 (2004).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99, 3554–3561 (2002).
   PubMed Web of Science ®Google Scholar
• Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer86, 2684–2692 (1999).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol.19, 1414–1420 (2001).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Kontoyiannis D et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma43, 1755–1762 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer98, 2657–2663 (2003).
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood98, 1721–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol.20, 205–213 (2002).
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood101, 4267–4272 (2003).
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood103, 2920–2924 (2004).
   PubMed Web of Science ®Google Scholar
• Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood62, 873–882 (1983).
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J.293(Pt 3), 633–640 (1993).
   PubMed Web of Science ®Google Scholar
• Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol. Biol. Med.1, 321–334 (1983).
   PubMedGoogle Scholar
• Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet2, 483–486 (1984).
   PubMed Web of Science ®Google Scholar
• Hale G, Cobbold S, Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation45, 753–759 (1988).
   PubMed Web of Science ®Google Scholar
• Hale G, Cobbold SP, Waldmann H, Easter G, Matejtschuk P, Coombs RR. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J. Immunol. Methods103, 59–67 (1987).
   PubMed Web of Science ®Google Scholar
• Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood73, 1431–1439 (1989).
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature332, 323–327 (1988).
   PubMed Web of Science ®Google Scholar
• James LC, Hale G, Waldmann H, Bloomer AC, Waldman H. 1.9 A structure of the therapeutic antibody CAMPATH-1H Fab in complex with a synthetic peptide antigen. J. Mol. Biol.289, 293–301 (1999).
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet2, 1394–1399 (1988).
   PubMed Web of Science ®Google Scholar
• Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (NY)9, 64–68 (1991).
   PubMedGoogle Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy3, 137–143 (2001).
   PubMed Web of Science ®Google Scholar
• Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J. Biol. Chem.270, 6088–6099 (1995).
   PubMed Web of Science ®Google Scholar
• Albitar M, Do KA, Johnson MM et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer101, 999–1008 (2004).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22, 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Hale G, Rye PD, Warford A, Lauder I, Brito-Babapulle A. The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J. Reprod. Immunol.23, 189–205 (1993).
   PubMed Web of Science ®Google Scholar
• Isaacs JD. The antiglobulin response to therapeutic antibodies. Semin. Immunol.2, 449–456 (1990).
   PubMedGoogle Scholar
• Hale G, Rebello P, Brettman LR et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood104, 948–955 (2004).
   PubMed Web of Science ®Google Scholar
• Cheetham GM, Hale G, Waldmann H, Bloomer AC. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol.284, 85–99 (1998).
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology95, 427–436 (1998).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood103, 1472–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21, 3940–3947 (2003).
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Modali R et al. FcRIγIIa and FcRγIIa polymorphisms may not correlate with response to alemtuzumab (Campath-1H) in chronic lymphocytic leukemia (CLL). Blood (2004) (In Press).
   Google Scholar
• Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res.63, 6453–6457 (2003).
   PubMed Web of Science ®Google Scholar
• Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J. Immunol. Methods260, 285–302 (2002).
   PubMed Web of Science ®Google Scholar
• Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy3, 261–267 (2001).
   PubMed Web of Science ®Google Scholar
• Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation68, 1417–1420 (1999).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol.15, 1567–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol.20, 3891–3897 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O’Brien SM, Cortes JE et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer98, 773–778 (2003).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol.93, 151–153 (1996).
   PubMed Web of Science ®Google Scholar
• Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol.96, 617–619 (1997).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukemia18, 1093–1101 (2004).
   PubMed Web of Science ®Google Scholar
• Montillo M, Cafro AM, Tedeschi A et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica87, 695–700 (2002).
   PubMed Web of Science ®Google Scholar
• Rai K, Byrd J, Peterson BL, Larson RA. A Phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer And Leukamia Group B (CALGB) study 19901. Blood100 (2002) (Abstract 205).
   PubMedGoogle Scholar
• Rai KR, Byrd JC, Peterson B, Gautier M, Larson RA. Subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. Blood102 (2003) (Abstract 676).
   PubMedGoogle Scholar
• Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood85, 1580–1589 (1995).
   PubMed Web of Science ®Google Scholar
• Cordone I, Masi S, Mauro FR et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood91, 4342–4349 (1998).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med.347, 452–453 (2002).
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood103, 3278–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol.15, 2667–2672 (1997).
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.16, 3257–3263 (1998).
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood101, 3413–3415 (2003).
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H et al. Results of a Phase II trial of a fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL. 2nd Interim analysis. Proc. Am. Soc. Clin. Oncol. USA23 (2004) (Abstract 603).
   Google Scholar
• Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood102, 1075–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am. J. Hematol.74, 227–230 (2003).
   PubMed Web of Science ®Google Scholar
• Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr. Blood Cancer (2004) (In Press).
   Google Scholar
• Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood103, 1969–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant13, 597–611 (1994).
   PubMed Web of Science ®Google Scholar
• Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant30, 797–804 (2002).
   PubMed Web of Science ®Google Scholar
• Naparstek E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol.89, 506–515 (1995).
   PubMed Web of Science ®Google Scholar
• Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood92, 4581–4590 (1998).
   PubMed Web of Science ®Google Scholar
• Kernan NA, Bordignon C, Keever CA et al. Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics. Transplant Proc.19, 29–32 (1987).
   PubMedGoogle Scholar
• Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol. Oncol. Clin. North Am.4, 687–698 (1990).
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Robinson S, Peggs K et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant28, 827–834 (2001).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R et al.In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood96, 2419–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood99, 1071–1078 (2002).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood99, 4357–4363 (2002).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Avivi I, Mackinnon S et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br. J. Haematol.119, 1125–1132 (2002).
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood100, 3121–3127 (2002).
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Rossi V et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia18, 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol.46, 296–304 (1999).
   PubMed Web of Science ®Google Scholar
• Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. CAMPATH-1H in inflammatory arthritis. Clin. Exp. Rheumatol.11(Suppl. 8), S165–S167 (1993).
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Yocum DE, Michalska M et al. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J. Rheumatol.24, 1031–1036 (1997).
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford)42, 1539–1544 (2003).
   PubMed Web of Science ®Google Scholar
• Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy3, 189–195 (2001).
   PubMed Web of Science ®Google Scholar
• Tzakis AG, Kato T, Nishida S et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation75, 1512–1517 (2003).
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation76, 120–129 (2003).
   PubMed Web of Science ®Google Scholar
• Keating M, Coutre S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma4, 220–227 (2004).
   PubMedGoogle Scholar
• Lundin J, Porwit-MacDonald A, Rossmann ED et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia18, 484–490 (2004).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N. Engl. J. Med.349, 2570–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood104, 655–658 (2004).
   PubMed Web of Science ®Google Scholar
• Basquiera AL, Berretta AR, Garcia JJ, Palazzo ED. Coronary ischemia related to alemtuzumab therapy. Ann. Oncol.15, 539–540 (2004).
   PubMed Web of Science ®Google Scholar
• Damaj G, Rubio MT, Audard V, Hermine O. Severe cardiac toxicity after monoclonal antibody therapy. Eur. J. Haematol.68, 324 (2002).
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Moreton P et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood103, 2027–2031 (2004).
   PubMed Web of Science ®Google Scholar